» Articles » PMID: 39258218

SARS-CoV-2 in Pregnancy, Birth and Puerperium. Guideline of the DGGG and DGPM (S2k-Level, AWMF Registry Number 015/092, March 2022)

Abstract

This S2k guideline of the German Society for Gynecology and Obstetrics (DGGG) and the German Society of Perinatal Medicine (DGPM) contains consensus-based recommendations for the care and treatment of pregnant women, parturient women, women who have recently given birth, and breastfeeding women with SARS-CoV-2 infection and their newborn infants. The aim of the guideline is to provide recommendations for action in the time of the COVID-19 pandemic for professionals caring for the above-listed groups of people. The PICO format was used to develop specific questions. A systematic targeted search of the literature was carried out using PubMed, and previously formulated statements and recommendations issued by the DGGG and the DGPM were used to summarize the evidence. This guideline also drew on research data from the CRONOS registry. As the data basis was insufficient for a purely evidence-based guideline, the guideline was compiled using an S2k-level consensus-based process. After summarizing and presenting the available data, the guideline authors drafted recommendations in response to the formulated PICO questions, which were then discussed and voted on. Recommendations on hygiene measures, prevention measures and care during pregnancy, delivery, the puerperium and while breastfeeding were prepared. They also included aspects relating to the monitoring of mother and child during and after infection with COVID-19, indications for thrombosis prophylaxis, caring for women with COVID-19 while they are giving birth, the presence of birth companions, postnatal care, and testing and monitoring the neonate during rooming-in or on the pediatric ward.

Citing Articles

Multiple Gestation as a Risk Factor for SARS-CoV-2-Associated Adverse Maternal Outcome: Data From the COVID-19 Related Obstetric and Neonatal Outcome Study (CRONOS).

Sourouni M, Germeyer A, Feisst M, Balzer A, Koster H, Minte A Geburtshilfe Frauenheilkd. 2023; 83(12):1508-1518.

PMID: 38046525 PMC: 10689107. DOI: 10.1055/a-2196-6224.

References
1.
Jimenez-Lozano I, Caro-Teller J, Fernandez-Hidalgo N, Miarons M, Frick M, Batllori Badia E . Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study. J Clin Pharm Ther. 2021; 46(4):1062-1070. PMC: 8014796. DOI: 10.1111/jcpt.13394. View

2.
Mulvey J, Magro C, Ma L, Nuovo G, Baergen R . Analysis of complement deposition and viral RNA in placentas of COVID-19 patients. Ann Diagn Pathol. 2020; 46:151530. PMC: 7182529. DOI: 10.1016/j.anndiagpath.2020.151530. View

3.
Servante J, Swallow G, Thornton J, Myers B, Munireddy S, Malinowski A . Haemostatic and thrombo-embolic complications in pregnant women with COVID-19: a systematic review and critical analysis. BMC Pregnancy Childbirth. 2021; 21(1):108. PMC: 7863033. DOI: 10.1186/s12884-021-03568-0. View

4.
Gurol-Urganci I, Jardine J, Carroll F, Draycott T, Dunn G, Fremeaux A . Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study. Am J Obstet Gynecol. 2021; 225(5):522.e1-522.e11. PMC: 8135190. DOI: 10.1016/j.ajog.2021.05.016. View

5.
Villar J, Ariff S, Gunier R, Thiruvengadam R, Rauch S, Kholin A . Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatr. 2021; 175(8):817-826. PMC: 8063132. DOI: 10.1001/jamapediatrics.2021.1050. View